Biotricity to Host Fiscal 2025 Fourth Quarter Financial Results and Business Update Call on July 18th
Biotricity (OTCQB:BTCY), a Technology-as-a-Service healthcare company, will host its Fiscal 2025 Fourth Quarter Financial Results and Business Update Call on July 18, 2025, at 4:45 PM ET. The company anticipates announcing its best financial performance to date, including improvements in margins, operational efficiency, and a shift to positive adjusted EBITDA.
CEO Dr. Waqaas Al-Siddiq and CFO John Ayanoglou will lead the presentation followed by a Q&A session. The call will be accessible via webcast and toll-free numbers, with replay available until August 1, 2025.
Biotricity (OTCQB:BTCY), un'azienda healthcare che offre Tecnologia come Servizio, terrà la sua presentazione dei Risultati Finanziari del Quarto Trimestre dell'Anno Fiscale 2025 e un aggiornamento aziendale il 18 luglio 2025 alle 16:45 ET. L'azienda prevede di annunciare la migliore performance finanziaria finora, con miglioramenti nei margini, nell'efficienza operativa e una transizione verso un EBITDA rettificato positivo.
Il CEO, Dr. Waqaas Al-Siddiq, e il CFO, John Ayanoglou, guideranno la presentazione seguita da una sessione di domande e risposte. La chiamata sarà accessibile tramite webcast e numeri verdi, con la possibilità di riascolto fino al 1° agosto 2025.
Biotricity (OTCQB:BTCY), una empresa de salud que ofrece Tecnología como Servicio, realizará su llamada de Resultados Financieros del Cuarto Trimestre del Año Fiscal 2025 y Actualización Comercial el 18 de julio de 2025 a las 4:45 PM ET. La compañía anticipa anunciar su mejor desempeño financiero hasta la fecha, incluyendo mejoras en márgenes, eficiencia operativa y un cambio hacia un EBITDA ajustado positivo.
El CEO, Dr. Waqaas Al-Siddiq, y el CFO, John Ayanoglou, dirigirán la presentación seguida de una sesión de preguntas y respuestas. La llamada estará disponible vía webcast y números gratuitos, con repetición disponible hasta el 1 de agosto de 2025.
Biotricity (OTCQB:BTCY)는 기술을 서비스로 제공하는 헬스케어 기업으로서, 2025 회계연도 4분기 재무실적 및 사업 업데이트 콜을 2025년 7월 18일 오후 4시 45분(동부시간)에 개최할 예정입니다. 회사는 마진 개선, 운영 효율성 향상, 그리고 조정 EBITDA 흑자 전환을 포함한 역대 최고의 재무 성과를 발표할 것으로 기대하고 있습니다.
CEO Dr. Waqaas Al-Siddiq와 CFO John Ayanoglou가 발표를 진행하며, 발표 후 질의응답 시간이 이어집니다. 콜은 웹캐스트와 무료 전화번호를 통해 참여할 수 있으며, 2025년 8월 1일까지 다시 듣기 서비스가 제공됩니다.
Biotricity (OTCQB:BTCY), une entreprise de santé proposant la technologie en tant que service, organisera sa conférence sur les résultats financiers du quatrième trimestre de l'exercice 2025 et une mise à jour commerciale le 18 juillet 2025 à 16h45 ET. La société prévoit d'annoncer ses meilleures performances financières à ce jour, incluant des améliorations des marges, de l'efficacité opérationnelle et une transition vers un EBITDA ajusté positif.
Le PDG Dr Waqaas Al-Siddiq et le directeur financier John Ayanoglou animeront la présentation suivie d'une séance de questions-réponses. L'appel sera accessible par webcast et numéros gratuits, avec une rediffusion disponible jusqu'au 1er août 2025.
Biotricity (OTCQB:BTCY), ein Healthcare-Unternehmen, das Technologie als Dienstleistung anbietet, wird seine Finanzergebnisse für das vierte Quartal des Geschäftsjahres 2025 und ein Unternehmensupdate am 18. Juli 2025 um 16:45 Uhr ET präsentieren. Das Unternehmen erwartet, seine beste finanzielle Leistung bisher bekannt zu geben, einschließlich Verbesserungen bei den Margen, der operativen Effizienz und einer Umstellung auf ein positives bereinigtes EBITDA.
CEO Dr. Waqaas Al-Siddiq und CFO John Ayanoglou werden die Präsentation leiten, gefolgt von einer Fragerunde. Der Anruf ist per Webcast und gebührenfreier Telefonnummer zugänglich, mit einer Wiedergabeoption bis zum 1. August 2025.
- None.
- None.
Company to announce improvements in Margins, Operational Efficiency, and a shift to positive Adjusted EBITDA
REDWOOD CITY, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, will host its Fiscal 2025 Fourth Quarter Financial Results and Business Update Call on July 18, 2025. The Company announces the best financial performance thus far and a shift to positive adjusted EBITDA. Biotricity’s Founder and CEO, Dr. Waqaas Al-Siddiq, and CFO, John Ayanoglou, will deliver remarks followed by a Q&A section to address questions from investors.
Event: Biotricity Fiscal 2025 Fourth Quarter Financial Results and Business Update Call
Date: Friday, July 18, 2025
Time: 4:45 PM ET (1:45 PM PT)
Toll Free: 1-877-269-7751
International: 1-201-389-0908
Webcast URL: https://viavid.webcasts.com/starthere.jsp?ei=1727799&tp_key=558b5c669d
Investors can begin accessing the webcast 15 minutes before the call, where an operator will register your name and organization. The call will be in listen-only mode.
A replay of the call will be available approximately 3 hours after the live call via the Investors section of the Biotricity website at https://biotricity.com/investors/.
Toll Free Replay Number: 1-844-512-2921
International: 1-412-317-6671
Replay Access ID: 13754989
Expiration: Friday, August 01, 2025 at 11:59 PM ET
About Biotricity Inc.
Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity’s unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” “project,” or “goal” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company’s future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand the Company’s business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. There cannot be any assurance that the Company will ever become profitable. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Contacts:
Investor relations:
Biotricity Investor Relations
Investors@biotricity.com
FAQ
When is Biotricity (BTCY) reporting Q4 2025 earnings?
How can investors access Biotricity's Q4 2025 earnings call?
What financial updates will Biotricity (BTCY) announce in Q4 2025?
How long will Biotricity's Q4 2025 earnings call replay be available?
